Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of operation of law in relation to the provision of adrenaline auto-injectors on commercial aircraft.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Following their review, the Adrenaline Auto-injector Expert Working Group (AAI EWG) recommended in principle that adrenaline auto-injectors (AAIs) should be made available in public locations, for use in treating anaphylaxis in unforeseen and critical circumstances, provided suitable safeguards can be implemented to ensure their effective and safe use. Challenges lie in ensuring correct and secure storage of AAIs, to ensure that the adrenaline does not deteriorate, and the device remains functional. Cinemas offering food for sale and other food outlets were identified as examples of locations where emergency AAIs might have particular potential to save lives.
The legislative change will therefore concern AAI supply, to specify or define individuals or organisations with the necessary competence to obtain and store AAIs for use in the event of an anaphylactic emergency. The AAI EWG advised the need for access to AAIs in a broad range of settings such as restaurants, gyms, cinemas, childcare facilities, youth groups, and music festivals. To support such wide-ranging access, the scope of legal supply will need to be linked to a requirement for training, to support safe use.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the Medicines and Healthcare products Regulatory Agency (MHRA), Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of operation of law in relation to the provision of adrenaline auto-injectors on trains.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Following their review, the Adrenaline Auto-injector Expert Working Group (AAI EWG) recommended in principle that adrenaline auto-injectors (AAIs) should be made available in public locations, for use in treating anaphylaxis in unforeseen and critical circumstances, provided suitable safeguards can be implemented to ensure their effective and safe use. Challenges lie in ensuring correct and secure storage of AAIs, to ensure that the adrenaline does not deteriorate, and the device remains functional. Cinemas offering food for sale and other food outlets were identified as examples of locations where emergency AAIs might have particular potential to save lives.
The legislative change will therefore concern AAI supply, to specify or define individuals or organisations with the necessary competence to obtain and store AAIs for use in the event of an anaphylactic emergency. The AAI EWG advised the need for access to AAIs in a broad range of settings such as restaurants, gyms, cinemas, childcare facilities, youth groups, and music festivals. To support such wide-ranging access, the scope of legal supply will need to be linked to a requirement for training, to support safe use.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the Medicines and Healthcare products Regulatory Agency (MHRA), Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what requirements there are for airlines to ensure adrenaline auto-injectors are available on commercial flights.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Following their review, the Adrenaline Auto-injector Expert Working Group (AAI EWG) recommended in principle that adrenaline auto-injectors (AAIs) should be made available in public locations, for use in treating anaphylaxis in unforeseen and critical circumstances, provided suitable safeguards can be implemented to ensure their effective and safe use. Challenges lie in ensuring correct and secure storage of AAIs, to ensure that the adrenaline does not deteriorate, and the device remains functional. Cinemas offering food for sale and other food outlets were identified as examples of locations where emergency AAIs might have particular potential to save lives.
The legislative change will therefore concern AAI supply, to specify or define individuals or organisations with the necessary competence to obtain and store AAIs for use in the event of an anaphylactic emergency. The AAI EWG advised the need for access to AAIs in a broad range of settings such as restaurants, gyms, cinemas, childcare facilities, youth groups, and music festivals. To support such wide-ranging access, the scope of legal supply will need to be linked to a requirement for training, to support safe use.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the Medicines and Healthcare products Regulatory Agency (MHRA), Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what requirements there are for airports to ensure adrenaline auto-injectors are available on their premises.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Following their review, the Adrenaline Auto-injector Expert Working Group (AAI EWG) recommended in principle that adrenaline auto-injectors (AAIs) should be made available in public locations, for use in treating anaphylaxis in unforeseen and critical circumstances, provided suitable safeguards can be implemented to ensure their effective and safe use. Challenges lie in ensuring correct and secure storage of AAIs, to ensure that the adrenaline does not deteriorate, and the device remains functional. Cinemas offering food for sale and other food outlets were identified as examples of locations where emergency AAIs might have particular potential to save lives.
The legislative change will therefore concern AAI supply, to specify or define individuals or organisations with the necessary competence to obtain and store AAIs for use in the event of an anaphylactic emergency. The AAI EWG advised the need for access to AAIs in a broad range of settings such as restaurants, gyms, cinemas, childcare facilities, youth groups, and music festivals. To support such wide-ranging access, the scope of legal supply will need to be linked to a requirement for training, to support safe use.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the Medicines and Healthcare products Regulatory Agency (MHRA), Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what guidance they have issued on the administering of adrenaline auto-injectors by minors in medical emergencies.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on the use of adrenaline auto-injectors in schools, and there is provision in this guidance for the use of an adrenaline auto-injector on someone to whom it was not prescribed, in a medical emergency. However, regulation 238 of the Human Medicines Regulations 2012 provides an exemption from certain requirements related to the administration of medicines. Specifically, it allows for parenteral, rather than injected or absorbed, administration of specified medicines in emergency situations, where the purpose is to save a life. For instance, adrenaline prescribed for a specific person, or even to an unknown person, can be administered under this regulation, if it is necessary to save a life during an emergency. The use in emergencies is covered by schedule 19 and regulation 238, where age is not specified.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the MHRA, Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what guidance they have issued regarding the use of an adrenaline auto-injector on someone to whom it was not prescribed in a medical emergency.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance on the use of adrenaline auto-injectors in schools, and there is provision in this guidance for the use of an adrenaline auto-injector on someone to whom it was not prescribed, in a medical emergency. However, regulation 238 of the Human Medicines Regulations 2012 provides an exemption from certain requirements related to the administration of medicines. Specifically, it allows for parenteral, rather than injected or absorbed, administration of specified medicines in emergency situations, where the purpose is to save a life. For instance, adrenaline prescribed for a specific person, or even to an unknown person, can be administered under this regulation, if it is necessary to save a life during an emergency. The use in emergencies is covered by schedule 19 and regulation 238, where age is not specified.
An Expert Advisory Group for Allergy was established in 2023, across the Government and clinical organisations, and chaired by the National Allergy Strategy Group and the Department, to recommend further action by the MHRA, Department of Health and Social Care, Department for Education, and the National Health Service. The Department of Health and Social Care and the MHRA are currently considering updates to the 2017 guidance, to ensure that any updated clarifications are supported by evidence, and that any open questions are answered.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what recent assessment they have made of any benefits gained from children's housing situations being tracked on the healthcare system to the adequacy of their healthcare.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government how many diagnoses the NHS has made of (1) anxiety, and (2) depression, in each of the past five years; and whether this information can be broken down by the type of accommodation of the patient.
Answered by Lord Kamall
The information is not held in the format requested, as the relevant datasets do not include data on diagnoses.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what steps they are taking, if any, to encourage those over the age of 75 who have not come forward for their Spring booster vaccination to do so.
Answered by Lord Kamall
Since March 2022, the National Health Service has invited more than five million eligible people in England to receive their COVID-19 spring booster dose, including those aged 75 years old and over, residents of care homes for older adults and those aged 12 years old and over who are immunosuppressed. As of 26 June 2022, over 4.2 million people have received a booster dose in the spring programme.
On 22 June 2022, NHS England issued an online press release urging eligible people to receive the booster vaccination. At the end of June, NHS England also sent approximately 250,000 reminders via text message, email and letter, advising that the booster vaccination offer remains available.
Asked by: Lord Kennedy of Southwark (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what assessment they have made of the data released by Skills for Care on 10 June that showed that (1) care home companies, and (2) local authorities, have high vacancy rates and are struggling with staff shortages within care homes.
Answered by Lord Kamall
We continue to monitor the monthly data released by Skills for Care with other operational data sources which indicate staff capacity in adult social care.
Skills for Care advise that its monthly data is unweighted and may not be representative, as it reflects those care providers which have updated the adult social care workforce dataset. The data does not include local authority staff responsible for assessments and the commissioning of care.